MétaCan
Menu
Back to cohort
Record W2950959781 · doi:10.82308/44576

Antithrombotic management in acute subdural hematoma

2017· article· en· W2950959781 on OpenAlexaboutno aff
Maryam Kia

Bibliographic record

VenueeScholarship@McGill (McGill) · 2017
Typearticle
Languageen
FieldMedicine
TopicNeurosurgical Procedures and Complications
Canadian institutionsnot available
Fundersnot available
KeywordsAntithromboticMedicineSubdural HematomasHematomaIntensive care medicineSurgeryInternal medicine

Abstract

fetched live from OpenAlex

Traumatic brain injuries and cardiovascular deficiencies are two of the leading causes of death in the U.S. Antithrombotics are among the common medications used for the management of cardiovascular diseases. However, the nature of antithrombotic agents makes the management of any bleeding difficult. Therefore, they are either not given to patients with a risk of bleeding, or they are stopped immediately in cases of bleeding.General guidelines in the case of intracranial hemorrhage (ICH) involve stopping the use of antithrombotics and then restarting them once the bleeding has stopped. However, unlike other types of intracranial hematomas, subdural hematomas (SDHs) are prone to rehemorrhage after a time (weeks or even months after the initial incident). Despite the prevalence of complications potentially caused by antithrombotic medications in the management of SDHs, this subject has yet to be fully investigated.This research paper documents for the first time the effects of antithrombotic therapies on patients suffering from SDHs. More specifically, we study the management of antiplatelet aggregation agents and anticoagulants in patients with traumatic SDHs. Understanding the risks of antithrombotics at different SDH stages (e.g. presence of active bleeding, presence of small or large residuals, and absence of residuals) helps to prevent potentially critical hemorrhagic complications. This thesis is a retrospective research study of patients who were admitted to the Montreal General Hospital with an acute traumatic SDH and who needed antithrombotic therapy. The study found that continuing therapeutic antiplatelet therapy while an SDH is still present, poses a high risk of rehemorrhage (45% for patients with a small residual SDH and up to 90% for those with a large residual SDH). The risk of rehemorrhage that will require neurosurgical intervention is 47%. ANTITHROMBOTIC MANAGEMENT IN ACUTE SDHOur data also shows that withholding AAA therapy for an average of 50 days, while the SDH is still present, does not contribute to any significant adverse event. We found similar results for anticoagulant therapy. The risk of rehemorrhage associated with restarting anticoagulant therapy if an SDH is not fully resolved is 28.5% and 62.5% for small and large residuals SDHs respectively. Our data shows that withholding anticoagulant therapy for an average of 67 days, while an SDH is still present, cause adverse events in only 1.1% of our study population.In the majority of cases our findings suggest that the safest course is to wait until the subdural hematoma has completely resolved before reinitiating antithrombotic therapy. At the same time, the status of the SDH should be closely monitored, using CT-scans, so that therapy can be reinitiated as soon as is safe. For patients with a high risk of thrombo-embolic events, it might be wiser to restart antithrombotic therapy while closely following-up the SDH with help of CT-scan imaging.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Theoretical or conceptual · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.792
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0010.000
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.028
GPT teacher head0.291
Teacher spread0.263 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designTheoretical or conceptual
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2017
Admission routes1
Has abstractyes

Explore more

Same venueeScholarship@McGill (McGill)Same topicNeurosurgical Procedures and ComplicationsFrench-language works237,207